▎Honor

James Chih-Hsin Yang, Chair Professor of the NTU Graduate Institute of Oncology and Superintendent at NTU Cancer Center, was bestowed the 2022 Paul A. Bunn Jr. Scientific Award from the International Association for the Study of Lung Cancer (IASLC) for his contributions to the understanding of epidermal growth factor receptor mutated nonsmall cell lung cancer. He received the award in person from IASLC’s President, Prof. Heather Wakelee, CEO, Prof. Karen Kelly and Prof. Paul A. Bunn at the opening ceremony of the World Conference of Lung Cancer (WCLC) 2022 in Vienna on August 6.

Yang is recognized for his many contributions to the application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) to EGFR mutated lung cancer patients. The large-scale clinical experiment on EGFR TKI that he led together with fellow Asian researchers helped establish EGFR TKI as the front-line treatment for lung cancer patients. Yang also lead trials that helped afatinib, the second-generation EGFR TKI, which later received internationally approved indication for the rare EGFR-mutant lung cancer. He also participated and lead early development of third-generation EGFR TKIs.

Yang is the 18^th scientist to receive this prestigious award, and he continues to pioneer lung cancer treatment through investigating new drugs and combination treatments. His works are the foundation of many current lung cancer treatment standards. As he continues to lead multidisciplinary medical and research teams to explore new treatments, he continues to save the lives of many cancer patients.